迈瑞医疗2024年三季报点评：海外保持增长国内短期承压

西部证券2024-12-04

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！海外保持稳健增长，国内短期承压。受益于海外高端战略客户和中大样本量实验室的突破，以及动物医疗、微创外科、AED 等种子业务的放量，国际市场前三季度增长超过18%，其中欧洲和亚太市场增长均超过了30%。国内因医疗领域整顿和医疗设备更新项目等多因素影响导致医院采购推迟，医院建设资金紧张和非刚性医疗需求低迷，国内市场前三季度增长...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2488131793?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-04 13:19","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2488131793","market":"sh","top_or_hot":-1,"title":"迈瑞医疗2024年三季报点评：海外保持增长 国内短期承压","media":"西部证券","content":"<html><body><div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 海外保持稳健增长，国内短期承压。受益于海外高端战略客户和中大样本量实验室的突破，以及动物医疗、微创外科、AED 等种子业务的放量，国际市场前三季度增长超过18%，其中欧洲和亚太市场增长均超过了30%。国内因医疗领域整顿和医疗设备更新项目等多因素影响导致医院采购推迟，医院建设资金紧张和非刚性医疗需求低迷，国内市场前三季度增长...</p>\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2024-12-04/doc-incyhpwv0735035.shtml\">网页链接</a>\n</div>\n</body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>迈瑞医疗2024年三季报点评：海外保持增长 国内短期承压</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n迈瑞医疗2024年三季报点评：海外保持增长 国内短期承压\n</h2>\n<h4 class=\"meta\">\n\n\n2024-12-04 13:19 北京时间   <a href=\"https://finance.sina.com.cn/stock/relnews/cn/2024-12-04/doc-incyhpwv0735035.shtml\"><strong>西部证券</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 海外保持稳健增长，国内短期承压。受益于海外高端战略客户和中大样本量实验室的突破，以及动物医疗、微创外科、AED 等种子业务的放量，国际市场前三季度增长超过18%，其中欧洲和亚太市场增长均超过了30%。国内因医疗领域整顿和医疗设备更新项目等多因素影响导致医院采购推迟，医院建设资金紧张和非刚性医疗需求低迷，国内市场前三季度增长...</p>\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2024-12-04/doc-incyhpwv0735035.shtml\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2348773727.SGD","symbol_name":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc SGD-H","start_time":0,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-12-04/doc-incyhpwv0735035.shtml","article_id":"2488131793","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488131793","pubTimestamp":1733289540,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"海外保持稳健增长，国内短期承压。受益于海外高端战略客户和中大样本量实验室的突破，以及动物医疗、微创外科、AED 等种子业务的放量，国际市场前三季度增长超过18%，其中欧洲和亚太市场增长均超过了30%。体外诊断前三季度增长超过 20%，受益于加速推动海外本地化生产和中大样本量实验室突破，国际体外诊断产线增长超过 30%，国内化学发光、生化、凝血等业务的市占率稳步提升。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300760":"迈瑞医疗","LU2348773727.SGD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE0005HP3H50.USD":"GUINNESS CHINA \"C\" (USD) ACC","BK0251":"专用设备","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","IE0008368742.USD":"首域中国增长基金I Acc","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","SGXZ81163826.USD":"UNITED CHINA A-SHARES INNOVATION \"A\" (USD) ACC","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU2153592121.USD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc USD","LU1720050803.USD":"安联全方位中国股票基金","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1734074674.USD":"NINETY ONE GSF ASIA PACIFIC FRANCHISE \"A\"(USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2153591404.USD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc USD","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU0823426308.USD":"法巴中国股票基金","LU0084288322.USD":"Natixis Asia Equity RD USD","LU2348774022.SGD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc SGD-H","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00B031J352.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) INC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","IE0031814852.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0594300419.USD":"富达中国消费基金A","LU1146622755.USD":"安本中国A股股票基金A Acc","SGXZ49509284.SGD":"United China A Shares Innovation A Acc SGD","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU2213484517.USD":"FRANKLIN TEMPLETON CHINA A-SHARES \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU0823426480.USD":"法巴中国股票经典Dis","LU2424517915.HKD":"abrdn SICAV I -  ASIAN SDG EQUITY \"A\" (HKD) ACC","IE00B29SXG58.USD":"FSSA CHINA FOCUS \"I\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359201612.USD":"贝莱德中国基金A2","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC"},"translate_title":"Comments on Mindray Medical's 2024 third quarterly report: Overseas growth maintains and domestic short-term pressure","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300760":1},"content_text":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 海外保持稳健增长，国内短期承压。受益于海外高端战略客户和中大样本量实验室的突破，以及动物医疗、微创外科、AED 等种子业务的放量，国际市场前三季度增长超过18%，其中欧洲和亚太市场增长均超过了30%。国内因医疗领域整顿和医疗设备更新项目等多因素影响导致医院采购推迟，医院建设资金紧张和非刚性医疗需求低迷，国内市场前三季度增长不到 2%。体外诊断实现高增长，超高端超声放量。体外诊断前三季度增长超过 20%，受益于加速推动海外本地化生产和中大样本量实验室突破，国际体外诊断产线增长超过 30%，国内化学发光、生化、凝血等业务的市占率稳步提升。医学影像前三季度增长超过10%，受益于去年底上市的全身应用超高端超声Resona A20 的放量，但国内超声的终端采购仍处于低迷状态，公司市占率进一步提升。生命信息与支持前三季度下滑超过10%，受益于海外高端战略客户的持续突破，国际生命信息与支持增长超过10%，但因招标采购推迟使得国内生命信息与支持产线下滑超过了20%，公司市占率有显著提升。投资建议：预计2024-2026 年公司收入389.89、464.12、543.14 亿元，同比增长11.6%、19.0%、17.0%；归母净利润134.48、158.02、185.57 亿元，同比增长16.1%、17.5%、17.4%；维持“增持”评级。风险提示：销售不及预期的风险；降价风险；汇率波动风险；产品研发风险；经营管理风险；经销商销售模式；中美贸易摩擦相关风险；行业政策变化\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.5","shortVersion":"4.31.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488131793"}

迈瑞医疗2024年三季报点评：海外保持增长 国内短期承压

精彩评论

迈瑞医疗2024年三季报点评：海外保持增长国内短期承压